Arena Therapeutics, Inc. announces $2.0 million in seed funding raised.

Arena Therapeutics, developer of an innovative approach to treat Parkinson's disease, announces the successful close of a $2 million seed funding round. The investors are passionate about advancing patient care and share the company's vision to address the unmet needs of individuals affected by Parkinson's disease.

Arena will apply this seed investment to accelerate the company's operations, secure additional intellectual property, and further advance compelling medical evidence that documents the benefits of Arena's investigational therapy.

This round of investment marks an important milestone, providing the company with the opportunity to prepare for its upcoming pivotal trial, said David Charles, MD, Chairman & Founder. "We believe our novel therapeutic approach has the potential to address a significant unmet need to potentially slow or stop the progression of Parkinson's motor symptoms and deliver substantial improvements in clinical outcomes. This backing from our investors validates our approach and allows us to accelerate our mission."

Arena Therapeutics has launched a Series A fundraising effort to support the enrollment of its pivotal clinical trial and the development of devices to advance its mission. Currently, there are no treatments that can slow or stop motor symptom progression for the 90,000+ early-stage Parkinson's Disease patients diagnosed yearly in the United States. Arena Therapeutics is a start-up focused on advancing Targeted Brain Modulation for the treatment of people diagnosed with Parkinson's disease, including early-stage patients. The Company is developing the only therapy targeting all stages of Parkinson's disease and has class II evidence indicating decreased risk of disease progression in people with early-stage disease.

CAUTION—Investigational device. Limited by United States law to investigational use only.